Search result for 'vikas gupta'

Wipro finalizes USD 375 mn acquisition of HARMAN's Digital Transformation Solutions. Expands AI, engineering capabilities.

Alkem Laboratories launches Pertuza, a biosimilar for HER2-positive breast cancer treatment in India. Affordable and indigenously developed.

Alkem Laboratories reports a 22% increase in Q1 net profit, reaching Rs 664 crore. Revenue up 11% driven by domestic & international growth.

Alkem Laboratories Q4 net profit rose 6% to Rs 322 crore, driven by domestic growth. FY25 profit reached Rs 2,215 crore. Dividend of Rs 8 per share announced.

Promoters of PG Electroplast sold a 5.3% stake in the company for Rs 1,132 crore through open market transactions. Singapore government and Motilal Oswal also acquired shares in the company.

The BSE Sensex has rebounded from its losses following the announcement of US reciprocal tariffs, driven by a surge in global markets and Trump's tariff relaxations.

Alkem Laboratories has launched a generic medication for type-2 diabetes, chronic kidney disease and heart failure in India under the brand name Empanorm, offering prices 80% lower than innovator...

Alkem Laboratories's Q3 net profit increased by 5% to Rs 626 crore, driven by higher sales. The company also acquired Adroit Biomed for Rs 140 crore.

Indian stock markets extended their winning streak for the third day, led by Reliance Industries and Bharti Airtel. Sensex closed at 76,759.81 and Nifty at 23,249.50.

Indian stock markets rose for the third day, led by gains in Reliance Industries, Bharti Airtel and HDFC Bank. Sensex gained 226.85 points, Nifty up 86.40 points.

Alkem Laboratories has signed a licensing agreement with Takeda to commercialize Vonoprazan, a drug for reflux esophagitis and other gastrointestinal conditions, in India.

Alkem Laboratories reports a 91% surge in net profit to Rs 550 crore in Q1 FY25, driven by strong sales. The company also highlights its focus on maximizing profitability and expanding its domestic...

Alkem Laboratories reported a four-fold surge in its consolidated net profit to Rs 293 crore for the March 2024 quarter, driven by lower raw material costs and price erosion in the US.